Drug intelligence / Profile preview

DWC202307 + DWC202216

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202307 + DWC202216 is an **investigational oral fixed-dose combination** being evaluated for its pharmacokinetics and safety in healthy adult volunteers. Both drugs, DWC202307 and DWC202216, are part of a series of candidate compounds developed by Daewoong Pharmaceutical, and are being studied for co-administration effects. Detailed pharmacology, targets, and indications for DWC202307 and DWC202216 are **not yet publicly disclosed**; their mechanisms and therapeutic focus areas are not reported in public databases or trial registries as of September 2025[1][5]. The combination is being tested in Phase 1 studies with crossover designs to evaluate interaction profiles.

Beyond the preview

Go deeper on DWC202307 + DWC202216.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202307 + DWC202216.

Explore the full profile